We are live on ! Find out more
SANA icon

Sana Biotechnology

177 hedge funds and large institutions have $581M invested in Sana Biotechnology in 2025 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 64 increasing their positions, 36 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

289% more capital inflows, than outflows

Capital inflows: $91M | Capital outflows: $23.4M

105% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 21

78% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 36

15% more funds holding

Funds holding: 154 → 177 (+23)

4.31% more ownership

Funds ownership: 64.47% → 68.77% (+4.3%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

11% less call options, than puts

Call options by funds: $1.48M | Put options by funds: $1.66M

Holders
177
Holders Change
+23
Holders Change %
+14.94%
% of All Funds
2.31%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
43
Increased
64
Reduced
36
Closed
21
Calls
$1.48​M
Puts
$1.66​M
Net Calls
-⁠$183​K
Net Calls Change
-⁠$973​K

SANA Hedge Fund Activity: Q3 2025 in Review

177 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q3 2025, worth a combined $581M — up 46% from $397M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new SANA positions and 21 closed out — a net gain of 22 holders — while 64 added to existing stakes and 36 trimmed.

The largest buyer was State Street, adding an estimated $13.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $8.72M.

  • 177 institutional investors held Sana Biotechnology (SANA) as of Q3 2025, up from 154 in Q2 2025.
  • Funds reported $581M of Sana Biotechnology stock for Q3 2025, up 46% quarter-over-quarter.
  • 43 funds opened new Sana Biotechnology positions in Q3 2025 and 21 closed out, a net change of +22 holders.
  • The largest Sana Biotechnology buyer in Q3 2025 was State Street, an estimated $13.8M added.
  • The largest Sana Biotechnology seller in Q3 2025 was T. Rowe Price Associates, an estimated $8.72M sold.

Based on aggregated 13F filings for Q3 2025.